(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

After Mikayla Nogueira unveiled her 60-pound weight loss transformation, the TikToker cleared the air on how she accomplished ...

While Ozempic is effective at treating type 2 diabetes and supporting weight loss, it can also come with side effects.

Shares in the maker of Ozempic crashed to three-year low after the pharma giant warned its injections were losing ground to ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

A growing number of people are turning to medications like Ozempic, Wegovy, and Mounjaro to aid in weight loss and manage ...

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.View ...

These semaglutide drugs became so popular after their efficacy for weight loss became apparent that, in a sense, they became ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.